This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Biotech ETFs to Gain on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
Can Top ETFs of Q2 Continue to Rally in Q3?
by Neena Mishra
We take a look at the best performing ETFs of Q2 that are likely to gain in Q3 as well.
Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.
Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak
by Sweta Jaiswal, FRM
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen
by Sweta Jaiswal, FRM
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
4 Sector ETFs Up More Than 30% in First-Half 2020
by Sweta Killa
We have highlighted four ETFs from various industries that were the star performers in the first half and are likely to continue their outperformance if the current trends continue.
Top & Flop Zones of First-Half 2020 and Their ETFs
by Sweta Killa
Inside the best and worst performing ETFs of first half.
New GERM ETF Launched to Tap the Growing Biotech Sector
by Sweta Killa
GERM invests in the hottest emerging biotechnology trends.
How Are Biotech ETFs Reacting to Coronavirus Treatment News?
by Sweta Jaiswal, FRM
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
5 ETFs Up More Than 20% in Three Months
by Sweta Killa
Wall Street has been performing impressively with the major indices climbing to a 12-week high. The rally was mainly powered by optimism over a potential coronavirus vaccine as well as an uptick in the economic activities as lockdown measures loosen.